The production of complex active pharmaceutical ingredients (APIs) continues to be one of the major technological challenges of the modern pharmaceutical industry. Many innovative medicines used in therapeutic areas such as oncology, infectious diseases, or viral pathologies are based on molecules of natural origin with highly complex chemical structures.
However, obtaining these molecules directly from natural sources is often unfeasible on a large scale. In addition to economic limitations, these methods also raise environmental concerns and create difficulties in ensuring a sufficient supply capable of meeting global demand.
On the other hand, the total chemical synthesis of these structures is also not without challenges. In many cases, it requires long synthetic routes with multiple stages, limited overall yields, and difficulties associated with impurity control or structural selectivity. In response to this scenario, an approach combining different technologies has emerged in recent decades to address these challenges more efficiently.
In this context, bioconversion through fermentation processes has established itself as an effective industrial platform for producing complex molecular intermediates from renewable raw materials. Fermentation processes make it possible to generate high-value compounds through optimized biological systems, supported by highly controlled upstream and downstream development strategies that ensure reproducibility, quality, and compliance with the regulatory standards of the pharmaceutical industry.
Although fermentation does not always allow the direct production of the final API, it facilitates the generation of complex structural building blocks that can subsequently be transformed through chemical processes.
This is where chemical synthesis plays a key role. Through carefully designed transformation steps, it enables the introduction of specific structural modifications and the achievement of the final molecule with the purity and quality profiles required by regulatory authorities.
The combination of fermentation and chemical synthesis therefore helps overcome many of the limitations inherent to each technology when used independently. The result is shorter, more efficient production routes with a lower environmental impact.
Several scientific reviews have highlighted the importance of integrating multiple technological platforms to develop sustainable and economically viable synthesis routes, particularly for molecules with high structural complexity relevant to modern therapeutics [1].
This integrated approach is progressively consolidating as a trend in API manufacturing, driven both by technological advances and by new industry requirements related to the sustainability of production processes and supply security.
At the same time, the adoption of green chemistry principles and process optimization has encouraged the development of new strategies aimed at reducing waste generation, minimizing resource consumption, and improving operational efficiency in pharmaceutical manufacturing [2].
In practice, this model is considered from the earliest stages of development through to industrial production, integrating biotechnological and chemical platforms within a single process design strategy.
Under this approach, fermentation enables the generation of complex molecular intermediates which, after subsequent chemical transformations, facilitate access to APIs that would otherwise be difficult to obtain efficiently using conventional methods.
This hybrid—yet convergent—manufacturing paradigm improves the robustness of the overall process, facilitates industrial scalability, and contributes to building more resilient supply chains. In addition, concentrating these capabilities within the same production environment makes it possible to optimize logistics, accelerate technology transfer, and reduce risks associated with the fragmentation of global supplier networks.
From a strategic and social perspective, this approach also aligns with the growing demands for sustainability, industrial resilience, and equitable access to advanced therapies. The combination of bioconversion through fermentation and chemical synthesis makes it possible to develop complex pharmaceutical solutions in an efficient and responsible manner, contributing to the advancement of global health and to strengthening a more sustainable and competitive pharmaceutical sector [3].
References
[1] Advances in the Synthesis and Optimization of Pharmaceutical APIs: Trends and Techniques.
Universal Journal of Pharmacy and Pharmacology, 4(1):1239, January 2025.
[2] Green Chemistry Approaches in Pharmaceutical Synthesis: Sustainable Methods for Drug Development.
AppliedChem, 5(2), 13, 2025.
[3] The Synergy of Fermentation and Chemical Synthesis in Active Pharmaceutical Ingredients (APIs) Manufacturing.
February 2024.
